ERR2208903
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0122214 | — | — | 0.875 |
| 2 | fe036511-fe82-467c-9c6e-59bfb8b0a329 | — | — | 0.870 |
| 3 | TCGA-CN-A49A-01A-11R-A24H-07 | — | — | 0.864 |
| 4 | SRR8613798 | — | D | 0.859 |
| 5 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.857 |
| 6 | ca7ac1e1-4c44-40a5-8094-eeebc0c2c5a2 | — | — | 0.854 |
| 7 | ERR2208936 | — | — | 0.848 |
| 8 | ca7940e6-af7e-44fd-a6fc-5d86dc1d86c4 | — | — | 0.848 |
| 9 | SRR10899993 | — | — | 0.843 |
| 10 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |